Condition: Gastric Cancer · Colon Cancer · Peritoneal Carcinomatosis · Sponsor: Technische Universität Dresden
Patients with gastric or colon cancer with peritoneal carcinomatosis will receive a biopsy of the tumor during their primary curative surgery. The operation is performed according to standard and includes resection of the primary tumor and any metastases and followed by HIPEC (Intraperitoneal hyperthermic chemoperfusion) according to the respective hospital standard. Organoid cultures from the biopsies are established in the research laboratory. Various chemotherapeutic agents are tested on these tumor organoids in the laboratory and the tumor organoids are analyzed in detail with regard to genetic alterations in order to find alterations that can be addressed, if necessary, by means of targeted drugs against peritoneal carcinomatosis.
This description comes directly from the study's public registry record.
Daniel Stange, Prof. Dr. · +49 351 458 4098 · daniel.stange@ukdd.de
Always discuss trial participation with your own doctor first.
| Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustv Carus Dresden | Dresden, Germany | Recruiting |
| University Hospital Heidelberg | Heidelberg, Germany | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05652348